Wegovy HD vs Zepbound: Does the Higher Dose Finally Match Tirzepatide?

For years, the simple version of the weight-loss drug story was that tirzepatide (Zepbound) beat semaglutide (Wegovy) on results. The new higher-dose Wegovy HD, at 7.2 mg, largely closes that gap. In trials, Wegovy HD produced about 20.7% average weight loss, and Zepbound has produced about 20.9%. Those numbers are close enough to call roughly even at the top end. The practical differences now have less to do with which is stronger and more to do with cost, dosing requirements, and who qualifies for each. If you’ve been choosing between them on the assumption that one clearly wins on weight loss, that assumption no longer holds at the highest doses.

Here’s how the two compare now that semaglutide has a higher gear.

The weight-loss gap has nearly closed

This is the headline change. The old comparison pitted Wegovy 2.4 mg (about 15%) against Zepbound’s top dose (about 21%), a real difference. Wegovy HD changes the math.

In the STEP UP trial, semaglutide 7.2 mg produced about 20.7% average weight loss over 72 weeks, with roughly one in three participants losing 25% or more (Wharton et al., Lancet Diabetes & Endocrinology 2025). Zepbound’s top dose produced about 20.9% in its trials. At the maximum doses, they’re essentially neck and neck.

A couple of caveats keep this honest. The two drugs were tested in separate trials, not head to head, so small differences shouldn’t be over-read. And tirzepatide’s evidence base is broad, including approval for obstructive sleep apnea based on its own large trial (Malhotra et al., NEJM 2024), which speaks to how thoroughly it’s been studied. But the era of assuming a big efficacy gap at the top doses is over.

Side by side

Cost and access

On self-pay cash price, Zepbound runs a bit cheaper. Wegovy HD costs $399 a month through NovoCare Pharmacy. Zepbound’s self-pay vials through LillyDirect cost $299 to $449 a month depending on dose, so the lower and middle doses undercut Wegovy HD, while the top doses land close to it. Our breakdown of Zepbound’s real pricing at retail and beyond covers how those numbers shake out across pharmacies.

With commercial insurance, both can drop to about $25 a month through their respective savings cards, assuming your plan covers them. And both are in the Medicare GLP-1 Bridge at about $50 a month for eligible Part D members starting July 1, 2026. The cash-pay difference favors Zepbound modestly; the insured and Medicare routes are a wash.

There’s also a meaningful access difference baked into the labels. Wegovy HD is a step-up dose: you can only get it after tolerating the 2.4 mg dose for at least four weeks and needing more reduction. Zepbound you start fresh at 2.5 mg and titrate up. So if you’re new to GLP-1 treatment and want the strongest option from a clean start, Zepbound is reachable sooner, while Wegovy HD requires building up through standard Wegovy first.

The other distinctions worth weighing

Beyond weight loss, each drug carries a different secondary credential. Wegovy (semaglutide) is the GLP-1 with the strongest cardiovascular evidence, approved to reduce the risk of heart attack and stroke in certain patients with established heart disease. Zepbound (tirzepatide) is approved for moderate-to-severe obstructive sleep apnea in adults with obesity, which can also matter for insurance coverage, since the sleep-apnea indication sometimes unlocks approval when weight-loss coverage is excluded.

Both share the class basics: a boxed warning for thyroid C-cell tumors, GI side effects led by nausea during dose increases, and the same caution against use with a personal or family history of medullary thyroid cancer or MEN-2.

Which one fits?

Consider a scenario where someone is starting from scratch, wants maximum weight loss, and has no coverage. Zepbound is reachable immediately, costs a bit less at the doses they’ll likely use, and matches Wegovy HD on results. That points toward Zepbound. Now consider someone already doing well on standard Wegovy who simply needs a stronger dose to finish the job, or who has cardiovascular disease where semaglutide’s heart data is relevant. That points toward stepping up to Wegovy HD.

For cash-pay patients, it’s worth comparing both brand routes against the compounded version of tirzepatide, which is often the lowest-cost path to that molecule. Our compounded tirzepatide pricing guide breaks down what to expect, and you can always start from the basics on our main program page.

TrimRx is a cash-pay telehealth program that connects you with licensed providers for physician-prescribed semaglutide and tirzepatide, with monthly pricing across the program’s medications running from $179 to $1,579 depending on the medication and plan. It works with both molecules through a flat monthly structure, no insurance required. To see which fits your situation, the free assessment quiz takes a few minutes and routes your information to a licensed provider for review.

This article is for general educational purposes and isn’t medical advice. These medications were studied in separate trials, carry a boxed warning, and aren’t appropriate for everyone. Drug pricing and programs change frequently, so verify current details with the manufacturers, your insurer, and your prescriber before making decisions.